Information Provided By: 
Fly News Breaks for February 28, 2020
AIMT
Feb 28, 2020 | 11:11 EDT
Roth Capital analyst Zegbeh Jallah noted that Aimmune management stated during their Q4 earnings update that 300 physicians have now been certified to deliver Palfrozia, which she sees as a strong indication of potential uptake. However, she also reminds investors that sales are more likely to begin ramping in Q2 than Q1 as formulary talks with insurers and batch releases are ongoing. The analyst, who said she remains bullish on Aimmune in 2020, has a Buy rating on the stock.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
